LH | Laboratory Corporation of America Holdings | [NYSE]
IndexS&P 500 P/E19.26 EPS (ttm)11.00 Insider Own0.10% Shs Outstand88.40M Perf Week-3.06%
Market Cap18.58B Forward P/E11.38 EPS next Y18.62 Insider Trans-17.91% Shs Float88.35M Perf Month-6.52%
Income1.00B PEG- EPS next Q4.22 Inst Own94.40% Short Float / Ratio1.83% / 2.82 Perf Quarter-11.46%
Sales14.76B P/S1.26 EPS this Y-42.70% Inst Trans-2.69% Short Interest1.61M Perf Half Y-12.20%
Book/sh116.99 P/B1.81 EPS next Y10.49% ROA5.00% Target Price273.08 Perf Year-15.28%
Cash/sh4.49 P/C47.17 EPS next 5Y-0.07% ROE9.80% 52W Range200.32 - 263.12 Perf YTD-10.00%
Dividend2.88 P/FCF17.37 EPS past 5Y15.40% ROI9.50% 52W High-19.46% Beta1.04
Dividend %1.36% Quick Ratio1.50 Sales past 5Y7.60% Gross Margin28.00% 52W Low5.80% ATR4.20
Employees80000 Current Ratio1.60 Sales Q/Q-3.10% Oper. Margin9.70% RSI (14)34.53 Volatility1.91% 1.74%
OptionableYes Debt/Eq0.53 EPS Q/Q-54.30% Profit Margin6.80% Rel Volume0.86 Prev Close215.60
ShortableYes LT Debt/Eq0.50 EarningsApr 25 BMO Payout0.00% Avg Volume571.83K Price211.93
Recom1.90 SMA20-3.88% SMA50-5.36% SMA200-8.39% Volume503,311 Change-1.70%
Date Action Analyst Rating Change Price Target Change
Dec-12-22Downgrade Citigroup Buy → Neutral $275 → $250
Sep-19-22Downgrade Argus Buy → Hold
Aug-22-22Resumed Morgan Stanley Overweight $300
Jan-28-22Downgrade Deutsche Bank Buy → Hold $330 → $294
Jan-11-21Upgrade Argus Hold → Buy $245
Jan-11-21Downgrade Wolfe Research Peer Perform → Underperform
Jan-08-21Downgrade Wolfe Research Outperform → Peer Perform
Jul-14-20Upgrade BofA Securities Neutral → Buy $194 → $220
Jul-13-20Upgrade Wolfe Research Peer Perform → Outperform
Jun-02-20Resumed Deutsche Bank Buy $210
May-26-23 06:52AM
06:32AM
May-25-23 11:30AM
May-17-23 02:15PM
May-16-23 02:32PM
10:59AM Loading…
10:59AM
07:00AM
May-12-23 06:02AM
May-06-23 08:13AM
May-04-23 06:56AM
May-03-23 06:59AM
Apr-29-23 09:53PM
Apr-27-23 05:48AM
Apr-26-23 08:14AM
12:05AM
01:39PM Loading…
Apr-25-23 01:39PM
12:10PM
09:30AM
09:23AM
08:05AM
06:52AM
Apr-19-23 07:32PM
Apr-17-23 09:52AM
Apr-13-23 03:30PM
Apr-11-23 12:59PM
12:44PM
Apr-09-23 08:19AM
Apr-06-23 06:51AM
Apr-04-23 12:35PM
Apr-03-23 08:00AM
10:30AM Loading…
Apr-02-23 10:30AM
Mar-31-23 06:59AM
Mar-19-23 01:49PM
Mar-14-23 12:46PM
Mar-08-23 10:18AM
Mar-07-23 07:14PM
Mar-06-23 12:51PM
Mar-04-23 08:25AM
Mar-02-23 05:00PM
Feb-22-23 09:00AM
Feb-20-23 08:18AM
Feb-18-23 07:15AM
Feb-17-23 03:01PM
05:09AM
Feb-16-23 03:02PM
01:29PM
11:00AM
10:41AM
09:56AM
08:35AM
07:12AM
07:00AM
Feb-14-23 07:59AM
Feb-09-23 02:54PM
07:42AM
07:00AM
Feb-07-23 12:21PM
10:36AM
Feb-06-23 11:47AM
06:05AM
Feb-03-23 01:58PM
08:53AM
08:24AM
Feb-01-23 11:44AM
11:43AM
10:03AM
09:40AM
Jan-31-23 10:32AM
Jan-30-23 09:25AM
08:31AM
Jan-27-23 10:40AM
Jan-26-23 10:08AM
10:07AM
08:03AM
Jan-25-23 11:31AM
Jan-24-23 11:50AM
Jan-23-23 10:31AM
09:30AM
Jan-18-23 04:28PM
09:57AM
Jan-17-23 08:43AM
Jan-16-23 09:40AM
Jan-12-23 04:22PM
Jan-10-23 09:40AM
Jan-09-23 09:19AM
Jan-05-23 02:08PM
07:00AM
Jan-03-23 07:28PM
04:29PM
Dec-15-22 08:46AM
Dec-12-22 09:25AM
Dec-09-22 02:11PM
09:30AM
Dec-08-22 04:30PM
11:20AM
Nov-28-22 06:08AM
Nov-15-22 12:41AM
Nov-14-22 09:23AM
Nov-07-22 12:32PM
Oct-31-22 04:26PM
Laboratory Corporation of America Holdings operates as a life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics and Labcorp Drug Development. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C and vitamin D, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, and parentage and donor testing; occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations (MCOs), including health fairs, on-site and at-home testing, vaccinations, and health screenings. In addition, the company offers online and mobile applications to enable patients to check test results; and online applications for MCOs and accountable care organizations; and end-to-end drug development, medical device, and companion diagnostic development solutions from early-stage research to clinical development and commercial market access. It serves MCOs, pharmaceutical, biotechnology, medical device and diagnostics companies, governmental agencies, physicians and other healthcare providers, hospitals and health systems, employers, patients and consumers, contract research organizations, and independent clinical laboratories. The company was incorporated in 1994 and is headquartered in Burlington, North Carolina.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kirchgraber Paul RCEO, Covance Drug DevelopmentMay 19Option Exercise182.514,300784,79317,246May 23 08:06 AM
Kirchgraber Paul RCEO, Covance Drug DevelopmentMay 19Sale216.914,300932,70712,946May 23 08:06 AM
Schroeder Mark SEVP, Pres Diagnostics & COOMay 18Option Exercise130.601,500195,9008,187May 22 03:08 PM
Schroeder Mark SEVP, Pres Diagnostics & COOMay 18Sale216.771,500325,1556,687May 22 03:08 PM
Schroeder Mark SEVP, President-Diagnostics LabMar 31Sale225.813,897879,9826,687Apr 03 10:05 AM
Kirchgraber Paul RCEO, Covance Drug DevelopmentFeb 21Option Exercise182.513,000547,53017,069Feb 23 09:54 AM
Kirchgraber Paul RCEO, Covance Drug DevelopmentFeb 21Sale250.588,0002,004,6759,069Feb 23 09:54 AM
Schroeder Mark SEVP, President-Diagnostics LabFeb 14Sale247.6330976,5186,687Feb 16 12:51 PM
Schroeder Mark SEVP, President-Diagnostics LabFeb 07Sale243.0140999,3916,687Feb 09 09:04 AM
van der Vaart Sandra DEVP, Chief Legal OfficerFeb 07Sale243.0121953,2195,341Feb 09 09:27 AM
Schroeder Mark SEVP, President-Diagnostics LabFeb 03Sale253.9032482,2646,687Feb 06 03:51 PM
van der Vaart Sandra DEVP, Chief Legal OfficerFeb 03Sale253.9017343,9255,341Feb 06 03:56 PM
Schroeder Mark SEVP, President-Diagnostics LabNov 08Sale232.671,116259,6606,687Nov 10 08:40 AM
EISENBERG GLENN AChief Financial Officer, EVPSep 26Sale210.6225,0005,265,57627,158Sep 28 09:12 AM
Caveney Brian JEVP, President of DiagnosticsSep 07Buy231.204410,25114,282Sep 13 11:39 AM
EISENBERG GLENN AChief Financial Officer, EVPAug 03Option Exercise147.1232,1004,722,54384,258Aug 05 09:52 AM
EISENBERG GLENN AChief Financial Officer, EVPAug 03Sale253.9432,1008,151,44952,158Aug 05 09:52 AM
Wilkinson Peter JSVP, Chief Accounting OfficerAug 01Option Exercise146.59767112,4352,654Aug 03 11:54 AM
Wilkinson Peter JSVP, Chief Accounting OfficerAug 01Sale258.402,576665,6351,887Aug 03 11:54 AM
Caveney Brian JEVP, President of DiagnosticsJun 07Buy242.194210,17414,172Jun 14 08:46 AM